Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-09
2007-10-09
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S106000, C544S111000, C544S132000, C544S140000, C546S268100, C546S275400, C548S356100, C548S364100, C514S231200, C514S336000, C514S341000, C514S406000
Reexamination Certificate
active
11030004
ABSTRACT:
Described herein are compounds that are useful as protein kinase inhibitors having the formula:where B, R1, n, R3, Q, and R4are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
REFERENCES:
patent: 5922741 (1999-07-01), Davis et al.
patent: 5932576 (1999-08-01), Anantanarayan et al.
patent: 6875789 (2005-04-01), Tang et al.
patent: WO98/52941 (1998-11-01), None
patent: WO 01/56993 (2001-08-01), None
patent: WO 01/57022 (2001-08-01), None
patent: WO 02/22610 (2002-03-01), None
Ambinter: “Screening Collection (catalog)”; Abstract, Accession No. 2001:326873 CHEMCATS, CAS Registry No. 321553-20-2; publication date Aug. 23, 1999.
Frey et al., “TGF-beta regulation of mitogen-activated protein kinases in human breast cancer cells,” Cancer Letters, 117(1):41-50 (1997).
Fukunaga et al., “Role of MAP kinase in neurons, ” Molecular Neurobiology, 16(1):79-95 (1998).
Hoshino et al., “Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors,” Oncogene, 18:813-22 (1999).
Illenberger et al. “The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease,” Molecular Biology of The cell, 9:1495-512 (Jun. 1998).
Kodama et al., “Significance of ERK Cascade compared with JAK/STAT and P13-K pathway in gp 130-medicated cardiac hypertrophy,” Am. J. Physiol. Heart Circ. Physiol., 279(4):H1635-44 (2000).
Kortylewski et al., “Mitogen-activated protein kinases control p27/Kip 1 expression and growth of human melanomacells,” Biochemical Journal, 357(Pt 1):297-303 (2001).
Kyosseva et al., “Mitogen-activated protein kinases in schizophrenia,” Society of Biological Psychiatry, 46(5):689-96 (1999).
Lee et al., “ICAM-I-induced expression of proinflammatory cytokines in astrocytes: involvement of extracellular signal-rgulated kinase kinase and p38 mitogen-activated protein kinase pathways,” The Journal of Immunology. 165(8):4658-66 (2000).
Namura et al., “Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia,” Proc. Natl. Acad. Sci. U.S.A. 98(20): 11569-74 (2001).
Putz et al., “Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor 1, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cella lines,” Cancer Research, 59(1):227-33 (1999).
Raghunandan et al., “Hyperphosphorylation of the cytoskeletal protein Tau by the MAP-kinase PK40erk2: regulation by prior phosphorylation with cAMP-dependent protein kinase A,” Biochemical and Biophysical Research Communications, 215(3);1056-66 (1995).
Slevin et al., “Activation of MAP kinase (ERK-1/Erk-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke,” NeuroReport 11(12):2759-64 (2000).
Pintucci et al., “Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells,” FASEB Journal 16(2):598-600 (2002).
Moses, et al., “Injury-induced osteopontin gene expression in rat arterial smooth muscle cells in dependent on mitogen-activated protein kinases ERK1/ERK2,” Archives of Biochemistry and Biophysics 396(1):133-137 (2001).
Wersinger and Sidhu, “Inflammation and Parkinson's Disease,” Current Drug Targets, 1(3): 221-242 (2002).
Hale Michael Robin
Janetka James Walter
Maltais Francois
Tang Oing
Pearson Daniel A
Shameem Golam M. M.
Vertex Pharmaceuticals Incorporated
LandOfFree
Pyrazole-derived kinase inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazole-derived kinase inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole-derived kinase inhibitors and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3872462